NEW YORK, Jan 22 – The bioinstrumentation sector is forecast to grow 15 percent this year to $4.3 billion, Strategic Directions International, a market research and consulting firm that tracks the instrument industry, said in a recent edition of its Instrument Business Outlook report.
Bioinstrumentation accounts for nearly 20 percent of all analytical instrument sales, SDI said. According to SDI bioinstrumentation includes all instruments for DNA sequencing, nucleic acid amplification, synthesis, electrophoresis and flow cytometry, as well as microarrays and biosensors.
Academics, pharmaceutical companies, and biotech firms are the leading users of bioinstrumentation. SDI noted that the DNA sequencers and microarrays are among the fastest growing markets.
SDI publishes the Instrument Business Outlook twice a month.